These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34454875)

  • 21. The Uncertain Benefit from Implantable Cardioverter-Defibrillators in Nonischemic Cardiomyopathy: How to Guide Clinical Decision-Making?
    Khan M; Jahangir A
    Cardiol Clin; 2023 Nov; 41(4):545-555. PubMed ID: 37743077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis.
    Jaiswal V; Taha AM; Joshi A; Deb N; Kanagala SG; Nebuwa C; Ang SP; Halder A; Rajak K; Jha M; Pallath Harshakumar S; Mattumpuram J
    Curr Probl Cardiol; 2024 Feb; 49(2):102198. PubMed ID: 37952790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Who still remains at risk of arrhythmic death at time of implantable cardioverter-defibrillator generator replacement?
    Madeira M; António N; Milner J; Ventura M; Cristóvão J; Costa M; Nascimento J; Elvas L; Gonçalves L; Mariano Pego G
    Pacing Clin Electrophysiol; 2017 Oct; 40(10):1129-1138. PubMed ID: 28842918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.
    Streitner F; Kuschyk J; Dietrich C; Mahl E; Streitner I; Doesch C; Veltmann C; Schimpf R; Wolpert C; Borggrefe M
    Clin Cardiol; 2011 Oct; 34(10):604-9. PubMed ID: 21887690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy in ischemic vs nonischemic cardiomyopathy patients.
    Abu Daya H; Alam MB; Adelstein E; Schwartzman D; Jain S; Marek J; Gorcsan J; Saba S
    Heart Rhythm; 2014 Apr; 11(4):614-9. PubMed ID: 24462657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
    Akel T; Lafferty J
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of cardiac resynchronization therapy by the frequency of revascularization procedures in ischemic cardiomyopathy patients.
    Husaini M; Biton Y; Stair B; Moss AJ; Biering-Sørensen T; Solomon S; McNitt S; Polonsky B; Zareba W; Barsheshet A; Kutyifa V
    Cardiol J; 2016; 23(4):437-45. PubMed ID: 27320956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-Year Outcomes of Primary Prophylactic Use of Defibrillators for Ischemic and Non-Ischemic Cardiomyopathy　- Propensity Score-Matched Analysis From the Nippon Storm Study.
    Kondo Y; Noda T; Takanashi Y; Sasaki S; Sato Y; Nitta T; Aizwa Y; Ohe T; Kurita T
    Circ J; 2024 Jun; 88(7):1107-1114. PubMed ID: 38057099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial Fibrosis Assessment by LGE Is a Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic and Nonischemic LV Dysfunction: A Meta-Analysis.
    Disertori M; Rigoni M; Pace N; Casolo G; Masè M; Gonzini L; Lucci D; Nollo G; Ravelli F
    JACC Cardiovasc Imaging; 2016 Sep; 9(9):1046-1055. PubMed ID: 27450871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
    Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
    Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of the Wearable Cardioverter-Defibrillator in Patients With Newly Diagnosed Cardiomyopathy: A Decade-Long Single-Center Experience.
    Singh M; Wang NC; Jain S; Voigt AH; Saba S; Adelstein EC
    J Am Coll Cardiol; 2015 Dec; 66(23):2607-2613. PubMed ID: 26670060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.
    Lee TC; Qian M; Mu L; Di Tullio MR; Graham S; Mann DL; Nakanishi K; Teerlink JR; Lip GYH; Freudenberger RS; Sacco RL; Mohr JP; Labovitz AJ; Ponikowski P; Lok DJ; Estol C; Anker SD; Pullicino PM; Buchsbaum R; Levin B; Thompson JLP; Homma S; Ye S;
    ESC Heart Fail; 2019 Apr; 6(2):297-307. PubMed ID: 30816013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [ECG score to predict ICD therapies in patients with nonischemic cardiomyopathy and primary prophylactic CRT-D].
    Grett M; Christ M; Röing Gen Nölke JP; Trappe HJ
    Herzschrittmacherther Elektrophysiol; 2017 Mar; 28(1):48-53. PubMed ID: 28204917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Saxena S; Goldenberg I; McNitt S; Hsich E; Kutyifa V; Bragazzi NL; Polonsky B; Aktas MK; Huang DT; Rosero S; Klein H; Zareba W; Younis A
    JAMA Netw Open; 2022 Jun; 5(6):e2217153. PubMed ID: 35699956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arrhythmia and Survival Outcomes among Black and White Patients with a Primary Prevention Defibrillator.
    Younis A; Ali S; Hsich E; Goldenberg I; McNitt S; Polonsky B; Aktas MK; Kutyifa V; Wazni OM; Zareba W; Goldenberg I
    medRxiv; 2023 May; ():. PubMed ID: 37205384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.
    Iles L; Pfluger H; Lefkovits L; Butler MJ; Kistler PM; Kaye DM; Taylor AJ
    J Am Coll Cardiol; 2011 Feb; 57(7):821-8. PubMed ID: 21310318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events.
    Szepietowska B; Polonsky B; Sherazi S; Biton Y; Kutyifa V; McNitt S; Aktas M; Moss AJ; Zareba W
    Cardiovasc Diabetol; 2016 Jul; 15():93. PubMed ID: 27388610
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.